SYLENTIS
Sylentis is a biotech company specializing in RNA interference (RNAi) technology to develop novel drugs, primarily for ocular diseases such as dry eye syndrome and macular degeneration. Founded in 2006 and part of the PharmaMar group, Sylentis uses proprietary AI-driven software, SirFinderTM, to design siRNA compounds with high silencing efficiency and specificity. The company offers RNAi-based drug discovery and development services, including CDMO manufacturing and regulatory support. Sylentis aims to improve patient quality of life by creating innovative RNAi therapeutics with a focus on eye health, leveraging a robust drug discovery platform to rapidly and cost-effectively develop therapies with potentially lower risk than traditional methods.
SYLENTIS
Sylentis is a biotech company specializing in RNA interference (RNAi) technology to develop novel drugs, primarily for ocular diseases such as dry eye syndrome and macular degeneration. Founded in 2006 and part of the PharmaMar group, Sylentis uses proprietary AI-driven software, SirFinderTM, to design siRNA compounds with high silencing efficiency and specificity. The company offers RNAi-based drug discovery and development services, including CDMO manufacturing and regulatory support. Sylentis aims to improve patient quality of life by creating innovative RNAi therapeutics with a focus on eye health, leveraging a robust drug discovery platform to rapidly and cost-effectively develop therapies with potentially lower risk than traditional methods.